Source comparison
BPC-157 Inflammation — Application Type Comparison
Subcutaneous (injury-adjacent) 200–500 mcg daily 48–72 hours (localized VEGF upregulation) Direct VEGFR-2 activation in target tissue; localized angiogenesis and collagen synthesis High. Peptide concentrates at injection site via interstitial diffusion before
This comparison does not assign a generated winner or score.
- Subcutaneous (injury-adjacent)
- 200–500 mcg daily
- 48–72 hours (localized VEGF upregulation)
- Direct VEGFR-2 activation in target tissue; localized angiogenesis and collagen synthesis
- High. Peptide concentrates at injection site via interstitial diffusion before systemic clearance
- Most effective for localized musculoskeletal inflammation (tendinopathy, ligament strain, muscle tear); allows precise tissue targeting
- Subcutaneous (systemic/abdominal)
- 3–5 days (systemic cytokine shift)
- Systemic VEGF and TGF-β upregulation; macrophage polarization from M1 to M2 phenotype
- Moderate. Distributed via circulation but less concentrated at any single tissue site
- Preferred for diffuse inflammation (IBD, systemic autoimmune flares); requires consistent daily dosing for sustained effect
- Oral (capsule)
- 500–1000 mcg daily
- 5–7 days (gut barrier repair)
- Direct mucosal contact; tight junction protein upregulation (claudin-1, occludin, ZO-1); reduced intestinal permeability
- Very high for GI tract; moderate for systemic (first-pass metabolism reduces bioavailability ~40–50%)
- Best for gut-specific inflammation (ulcerative colitis, Crohn's, leaky gut syndrome); less effective for musculoskeletal issues due to lower systemic availability
- Topical (cream/gel formulation)
- Variable (typically 0.01–0.1% w/w)
- Minimal systemic effect
- Localized skin penetration limited to dermis; minimal VEGF activation due to poor transdermal absorption of peptides >500 Da
- Very low. Peptides of BPC-157's molecular weight (~1419 Da) penetrate stratum corneum poorly without penetration enhancers
- Not recommended as primary treatment; may provide minor localized effect for superficial skin inflammation but lacks evidence for deeper tissue penetration